Nimbus Therapeutics has entered a collaboration and licensing agreement with Eli Lilly for potential therapeutics for metabolic diseases with a potential value of $496 million.
The two companies will collaborate on the development of novel targeted therapies designed to activate a specific isoform of AMPK for the potential treatment of metabolic diseases. AMPK (AMP-activated protein kinase) is considered a high-value target in this indication due to its role in glucose, lipid metabolism, and inflammation.
The companies will work to identify isoform-selective, small molecule activators of AMPK heterotrimers, believed to improve glucose and lipid homeostasis while mitigating safety concerns.
Nimbus will apply its computational drug discovery engine to develop isoform-selective small molecule AMPK activators applicable in a broad range of metabolic diseases, leveraging Lilly
